Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury
Independent from GLP1 Receptor Signaling by Remm, Friederike et al.
Research Article
Sitagliptin Accelerates Endothelial Regeneration after Vascular
Injury Independent from GLP1 Receptor Signaling
Friederike Remm ,1 Nicolle Kränkel,2,3 Daniela Lener,1 Daniel J. Drucker ,4
Sieghart Sopper ,5 and Christoph Brenner 1,6
1Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria
2Department of Cardiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
3DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada
5Department of Internal Medicine V, Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria
6Department of Cardiology, Reha Zentrum Muenster, Münster, Tirol, Austria
Correspondence should be addressed to Christoph Brenner; mail@med.cbrenner.net
Received 17 August 2017; Revised 23 November 2017; Accepted 2 December 2017; Published 8 February 2018
Academic Editor: Mingfu Wu
Copyright © 2018 Friederike Remm et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Introduction. DPP4 inhibitors (gliptins) are commonly used antidiabetic drugs for the treatment of type 2 diabetes. Gliptins also act
in a glucose-independent manner and show vasoregenerative eﬀects. We have shown that gliptins can remarkably accelerate
vascular healing after vascular injury. However, the underlying mechanisms remain unclear. Here, we examined potential
signaling pathways linking gliptins to enhanced endothelial regeneration. Methods and Results. We used wild-type and GLP1
receptor knockout (Glp1r−/−) mice to investigate the underlying mechanisms of gliptin-induced reendothelialization. The
prototype DPP4 inhibitor sitagliptin accelerated endothelial healing in both animal models. Improved endothelial growth was
associated with gliptin-mediated progenitor cell recruitment into the diseased vascular wall via the SDF1-CXCR4 axis
independent of GLP1R-dependent signaling pathways. Furthermore, SDF1 showed direct proproliferative eﬀects on endothelial
cells. Excessive neointimal formation was not observed in gliptin- or placebo-treated Glp1r−/− mice. Conclusion. We identiﬁed
the SDF1-CXCR4 axis as a crucial signaling pathway for endothelial regeneration after acute vascular injury. Furthermore, SDF1
can directly increase endothelial cell proliferation. Gliptin-mediated potentiation of endothelial regeneration was preserved in
Glp1r−/− animals. Thus, gliptin-mediated endothelial regeneration proceeds through SDF-1/CXCR4 in a GLP1R-independent
manner after acute vascular injury.
1. Introduction
Gliptins are inhibitors of the dipeptidyl peptidase-4 (DPP4)
enzyme and have demonstrated a vasoprotective and vasore-
generative impact after endothelial injury and during early
atherosclerosis. Various preclinical and clinical studies have
conﬁrmed these favorable eﬀects [1–6]. Several gliptins are
clinically approved as antidiabetic drugs for the treatment
of type 2 diabetes mellitus (T2DM). However, the underly-
ing mechanisms of their vasoregenerative eﬀects are not
completely understood [7]. Some clinical trials have con-
ﬁrmed a good safety proﬁle for the use of gliptins in diabetic
[8–10] and nondiabetic patients [11]. Together with our
previously published preclinical data, gliptins appear to be
promising agents for the treatment of vascular diseases.
Several pathways and substrates may explain the positive
gliptin-mediated eﬀects on the vascular system. These
include the inhibition of glucagon-like peptide 1 (GLP1)
and stromal cell-derived factor 1 (SDF1) degradation. The
latter is responsible for the recruitment of circulating progen-
itor cells (ciPC) via the SDF1-CXCR4 pathway [3, 12–15].
In our previous studies, we have shown that sitagliptin
can enhance endothelial regeneration after vascular injury.
We veriﬁed the SDF1-CXCR4 signaling as the underlying
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regenerative cellular mechanism. SDF1, a physiological
DPP4 substrate, is expressed by adhesive thrombocytes,
vascular smooth muscle cells, and activated endothelial cells
[16–18]. SDF1 binds to CXCR4 on the surface of ciPC and
recruits them to the sites of vascular injury. Here, ciPC can
induce resident endothelial cell proliferation via paracrine
mechanisms in the border zone of the injured area. Gliptins
prevent cleavage of SDF1 by inhibiting DPP4 activity, which
leads to an increase of local SDF1 concentrations [3, 19, 20].
Nevertheless, inhibition of DPP4 degradation with sitagliptin
does not lead to progenitor cell recruitment in atherosclerotic
lesions. The protective impact of gliptin treatment led to the
priming of monocyte diﬀerentiation towards cholesterol-
exporting M2 macrophages. These cells can inhibit progres-
sion of atherosclerotic plaque formation, which explains the
sitagliptin-mediated vasoprotection in chronic endothelial
injury [2].
The incretin GLP1 is another important DPP4 substrate,
which is inactivated by N-terminal enzymatic cleavage [21].
Besides its function in glucose metabolism, GLP1 might have
additional protective and regenerative eﬀects on the vascular
system. These could be explained by its positive inﬂuence on
endothelial function, blood lipid proﬁles, and vascular
inﬂammation [13, 22–24]. Since both SDF1 and GLP1 are
DPP4 substrates, pharmacological inhibition of DPP4 leads
to an increase of circulating levels of both active GLP1 and
SDF1. To dissect the contributions of gliptin-based signaling
pathways, we used Glp1r−/− mice and investigated the rele-
vance of GLP1 receptor signaling in endothelial regeneration.
2. Material and Methods
2.1. Scratch Assay. For the evaluation of endothelial cell pro-
liferation, human umbilical endothelial vein cells (HUVECs;
Promo Cell, Heidelberg, Germany) were grown until they
formed a cellular monolayer. After creating scratches with a
100μl pipette tip, the cells were incubated with recombinant
human CXCL12/SDF1 (R&D Systems, Minneapolis, USA)
in diﬀerent concentrations (0 ng/ml, 1 ng/ml, 10 ng/ml, and
100ng/ml) SDF1 for 24h. Subsequently, photos were taken
with a light microscope (Leica, Wetzlar, Germany).
2.2. DPP4 Activity Assay. To perform DPP4 activity mea-
surements, we used a DPP4 Activity Fluorometric Assay
Kit following the manufacturer’s instructions (BioVision,
Milpitas, USA). Serum was taken from Glp1r−/− mice after
three days of oral sitagliptin administration (n = 4 (pooled),
3 mice each sample). Serum from placebo-treated mice
collected at the same point served as reference. DPP4 activity
measurements using the Fluorometric Assay Kit were
previously established by our group and veriﬁed using mass
spectrometry [3].
2.3. Animal Experiments. All animal experiments were
approved by the Austrian Federal Ministry of Science,
Research and Economy (authorization number BMWFW-
66.011/0160-WF/V/3b/2014). We used Glp1r−/− mice with
a C57Bl/6N genetic background in our experiments.
Glp1r−/− mice emerged from an in-house breeding
originating from 9 female and 4 male Glp1r−/− mice
(Taconic, Lille Skensved, Denmark). Dr. Daniel Drucker
(Lunenfeld-Tanenbaum Research Institute, Toronto, Canada)
created the Glp1r−/− animals and provided them for our
experiments [25, 26]. C57Bl/6 mice were delivered by a
commercial breeder (Charles River, Sulzfeld, Germany).
2.4. Administration of Sitagliptin and AMD3100. To ensure a
dose of 500mg/kg/d sitagliptin, we fed a premixed chow con-
taining 2550mg sitagliptin per kg chow (Ssniﬀ Spezialdiäten,
Soest) to the animals ad libitum. We calculated the sitagliptin
food concentration based on an average daily food intake of
4.9 g/day/mouse as previously described [2, 3, 27].
For the administration of the CXCR4 blocker AMD3100
(1.25mg/kg/d; Sigma-Aldrich, St. Louis USA), we chose
subcutaneous injections. We have previously determined an
optimized dose that is able to block the CXCR4 receptor on
circulating progenitor cells without mobilizing progenitor
cells from bone marrow [27].
2.5. Carotid Injury and Quantiﬁcation of Endothelial
Regeneration.We induced endothelial lesions in the common
carotid arteries as previously described [28] under isoﬂurane
anesthesia. In brief, we induced a 4mm long endothelial
injury of the left common carotid artery in 9–12-week-old
mice (n = 9/group) using a bipolar microregulator (Vio50C,
ERBE Elektromedizin, Tübingen, Germany) with a power
of 2W for 0.5 seconds at the left common carotid artery.
Randomization allocated the mice into four treatment
groups: placebo (Plac), sitagliptin (Sita), AMD3100 (AMD),
and sitagliptin and AMD3100 (SitaAMD).
Three days after carotid injury, we evaluated reendotheli-
alization by the quantiﬁcation of the regenerated area using
Evans blue staining as previously described [3]. Shortly, we
injected 100μl of a 5% Evans blue solution (Sigma-Aldrich,
St. Louis, USA) to the anesthetized mice via the tail vein
and scariﬁed the mice 2 minutes later for harvesting the
common carotid artery. Evans blue stained the remaining
deendothelialized area. We calculated the reendothelializa-
tion as the reendothelialized area divided by the area of initial
injury [3].
2.6. Flow Cytometry Analyses. Three days after carotid injury,
carotid arteries were subjected to ﬂow cytometry-based
characterization using a protocol modiﬁed from an earlier
described one [3], in order to increase detectability of the
ciPC. Brieﬂy, we harvested the left (selective injured area)
and right (uninjured) carotid arteries and minced the vessels
with microsurgical scissors. To obtain a suﬃcient amount
of cells, we pooled two arteries per sample (n = 8/group)
and incubated them in a 0.2% collagenase (Worthington)
and 0.01% DNAse (Roche, Basel, Switzerland) solution
45 minutes for digestion. After washing in PBS, we stained
the single-cell solution with the following antibodies for
the detection of ciPC: PE-anti-CXCR-4 (BD Pharmigen,
Heidelberg, Germany), BV421-anti-CD133 (BioLegend, San
Diego, USA), APC-anti-Flk-1 (BD Pharmigen), and V500-
anti-CD45, and analyzed with an LSRFortezza ﬂow
cytometer (BD Biosciences) [3, 29, 30]. The previously
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established antibody staining was reﬁned by an extensive
antibody titration protocol [3]. Furthermore, we used anti-
bodies against F4/80, Gr1, and CD206 (PE-F4/80, BV421-
Gr-1, and APC-CD206; all BioLegend and V500-CD45; BD
Horizon) for the detection of M1 and M2 macrophages [2].
2.7. Histological Evaluation of Neointimal Formation. For the
histological evaluation of gliptin-mediated eﬀects on neoin-
tima formation after endothelial injury, we sacriﬁced mice
(n = 8/group) 28 days after carotid injury. Sitagliptin- and
sitagliptin and AMD3100 treatments were provided in this
experiment over a period of 6 days after acute endothelial
injury. We then cut the Tissue-Tek® O.C.T. compound-
embedded (Sakura Fintek, Torrance, USA) carotid arteries
into 5μm sections (6 to 8 per mouse, cryo-sections). For
the Weigert’s Elastica van Gieson staining of the serial
sections, we used a commercial staining kit (DiaPath,
Martinengo, Italien) and analyzed neointimal formation by
measuring the sections planimetrically. Finally, we calculated
the “intima (I)-to-media (M) ratio” and the “intima+media
to total cross section (tcs),” “I/I +M,” and “(I +M)/tcs”.
2.8. Statistical Analyses. For the estimation of the sample size
for the experiments (reendothelialization, ﬂow cytometry,
and histology), we used “Power and Sample Size Program
version 3.1.2, July 2014” [31]. We used ImageJ software for
the morphometric analyses, and GraphPad Prism software
(version 7) for statistical analyses. The results are expressed
as means with standard error, and normality and variances
of equality are conﬁrmed for multiple group comparisons.
One-way-analysis of variances (ANOVA) followed by the
Bonferroni correction was used for multiple group compari-
sons, and for the comparison of two groups, we used
unpaired Student’s t-test. Diﬀerences were regarded signiﬁ-
cant at a p value of ≤0.05.
3. Results
3.1. Sitagliptin Inhibits DPP4 Activity in Glp1r−/− Mice. We
ﬁrst conﬁrmed that sitagliptin administration of 500mg/kg/d
led to a suﬃcient inhibition of DPP4 activity inGlp1r−/−mice
compared to untreated controls. Sitagliptin administration
led to a reduction of DPP4 activity from 141.92± 19.11 rela-
tive ﬂuorometric units (RFUs) to 1.22± 0.71 RFUs (Figure 1).
3.2. Quantiﬁcation of Endothelial Regeneration. Three days
after carotid injury, we observed accelerated endothelial
regeneration in the sitagliptin-treated mice (Glp1r−/− and
C57Bl/6N). In the Glp1r−/− animals, sitagliptin led to a signif-
icantly larger reendothelialized area (r.a., 48.0%± 2.61) than
placebo treatment (20.5%± 3.57 r.a.). Sitagliptin-treated
wild-type mice also showed signiﬁcantly better vascular
regeneration (41.1%± 4.05 r.a.) as compared to wild-type
placebo group (17.2%± 2.86 r.a.; Figures 2(a) and 2(b))
whereas Glp1r−/− mice did not show a quantitative diﬀer-
ence in endothelial healing compared to the C57Bl/6
wild-type controls.
Cotreatment with the CXCR4 blocker AMD3100
completely abolished the sitagliptin-elicited improvement of
endothelial regeneration in Glp1r−/− mice (26.9%±2.77 r.a.).
However, AMD3100 alone did not signiﬁcantly aﬀect
endothelial regeneration in the placebo-treated Glp1r−/−
(11.55%± 1.39 r.a.) and wild-type (18.52± 1.58) mice
(Figures 2(a) and 2(b)).
3.3. Quantiﬁcation of Circulating Progenitor Cells.Using ﬂow
cytometry analyses of the injured carotid arteries, we
detected an increased recruitment of ciPC in sitagliptin-
treated Glp1r−/− mice compared to the placebo group.
This was true for CXCR4+CD133+- (28.9%± 3.41) and
CXCR4+Flk-1+- (30.9%± 3.27) recruited progenitor cells
in the arterial wall of sitagliptin-treated mice compared
to the placebo group (CXCR4+CD133+ 9.8%± 1.84 and
CXCR4+Flk-1+ 10.41%± 1.96). Consistent with the reendo-
thelialization assays, an addition of the CXCR4 blocker
AMD3100 abolished progenitor cell recruitment in
sitagliptin-treated Glp1r−/− mice and resulted in the recruit-
ment of 12.2%± 4.64 CXCR4+CD133+ or 13.5%± 5.22
CXCR4+Flk-1+ ciPC (Figures 3(a) and 3(b)). Uninjured
carotid arteries showed a comparably low proportion of
recruited progenitor cells that were independent from the
treatment with sitagliptin or AMD3100 (see Figures 3(c)
and 3(d)).
3.4. Neointimal Formation in Carotid Arteries. 28 days
after endothelial injury placebo-, sitagliptin-, and sitagliptin
and AMD3100-treated Glp1r−/− mice showed no diﬀerences
in the extent of neointima formation (Figure 4). Neither
“intima-to-media ratio” (Plac 0.1± 0.008; Sita 0.08± 0.006;
and SitaAMD 0.09± 0.011) nor “intima+media to total cross
section” (Plac 0.49± 0.05; Sita 0.43± 0.04; and SitaAMD
0.38± 0.04) showed signiﬁcant diﬀerences between the
treatment groups.
3.5. Quantiﬁcation of M1 and M2 Macrophages. Sitagliptin
treatment had no eﬀect on total macrophage content or
macrophage subtypes in the injured carotid artery wall of
Glp1r−/− mice three days after carotid injury. The placebo
group showed a total macrophage content (F4/80+ cells) of




















Figure 1: Administration of oral sitagliptin over a period of three
days signiﬁcantly reduced serum DPP4-activity (∗∗∗p ≤ 0 001).
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58.6%± 5.55 F4/80+ cells, and the sitagliptin and AMD3100
group 62.8%± 3.27. Analyses of the uninjured carotid arter-
ies resulted in a minor proportion of F4/80+ macrophage
content (Plac 37.9%± 6.62; Sita 37.3%± 5.38; and SitaAMD
38.5%± 5.74) which also did not diﬀer signiﬁcantly between
the groups (Figures 5(a) and 5(b)).
Furthermore, the proportion of inﬂammatory F4/80+
Gr-1+ M1 (Plac 10.4%± 1.04; Sita 8.6%± 1.8; and SitaAMD
10%± 2.23) and regenerative F4/80+CD206+ M2 macro-
phages (Plac 28.5%± 6.04; Sita 29.8%± 3.86; and SitaAMD
33.9%± 3.84) in the injured carotid artery did not diﬀer
signiﬁcantly between groups (Figures 5(c) and 5(d)).
3.6. SDF1 Exerts Direct Proproliferative Eﬀects on Endothelial
Cells. 24 h after scratching, the HUVEC monolayer showed a
signiﬁcantly better scratch closure if incubated with SDF1
(10ng/ml and 100ng/ml). Compared to placebo control
(11.6%± 1.38 scratch closure), cells incubated with 10ng/ml
SDF1 showed a scratch closure of 34.9%± 1.38 after 24 h.
100ng/ml SDF1 led to a scratch closure of 35.5%± 1.76. In
contrast, the lower concentration of 1 ng/ml SDF1 only
evinced a scratch closure of 14.7%± 1.12 (Figure 6).
4. Discussion
DPP4 inhibitors mediate their vasoprotective impact via
various molecular pathways and cellular mechanisms. Glip-
tins inhibit cleavage of the incretin GLP1 and the cytokine
SDF1. While SDF1 acts via the SDF1-CXCR4 signaling
pathway, GLP1 might mediate vascular protection via a
GLP1R/cAMP-dependent activation of the AMPK/PI3K-
Akt/eNOS pathway [32]. Both molecules are important
potential factors in the diseased vascular system [33]. In
previous studies, we have shown that DPP4 inhibition leads
to an increase in local SDF1 concentration after endothelial
injury. SDF1 improves the recruitment of regenerative
progenitor cells which can mediate an accelerated vascular
healing [3]. However, it is yet unclear whether concomitant
inhibition of GLP1 cleavage may have supported this regen-
erative eﬀect. Therefore, we further investigated vascular
healing in a homozygous knockout mouse model lacking
the GLP1 receptor.
4.1. Endothelial Regeneration Is Preserved in Glp1r−/− Mice.
GLP1 appears to have a protective inﬂuence on the vascular
system. Liu et al. postulate several mechanisms for GLP1-
mediated improvement in endothelial function. These
include upregulation of NO synthesis, reduction of reactive
oxygen species (ROS), and cyclooxygenase 2 expression
(COX2) [34]. Similar eﬀects like reduced vascular inﬂamma-
tion, lower ROS expression, and improved endothelial
dysfunction were described previously by Ceriello et al. as
well [13]. Furthermore, Torimoto et al. reported GLP1-
mediated reduced postprandial triglyceride levels (TG) in
human T2DM patients and therefore suggested indirect
antiatherogenic eﬀects of GLP1 [35]. Hence, it seems likely
that the sitagliptin-mediated improved endothelial regenera-









































































Figure 2: (a) Sitagliptin treatment signiﬁcantly improved endothelial regeneration compared to placebo treatment in both, Glp1r−/− (GLP)
and C57Bl/6N wild-type (Bl6) mice. Additional treatment with the CXCR4 receptor blocker AMD3100 abolished the positive gliptin eﬀect
completely (n.s. = not signiﬁcant; ∗∗p ≤ 0 01 and ∗∗∗∗p ≤ 0 0001). (b) Evans blue staining of the injured carotid arteries three days after
carotid injury (d0 = day 0; P = placebo; S = sitagliptin; AMD=AMD3100; and S & AMD= sitagliptin and AMD3100).















































































































































































































































0 102 103 104 105
0 102 103 104 105
<r 670/14 A>: CD133
0 102 103 104 105
<r 670/14 A>: CD133
0 102 103 104 105
<r 670/14 A>: Fkl-1
0 102 103 104 105
<r 670/14 A>: Fkl-1
0 102 103 104 105
(e)
Figure 3: (a, b) The DPP4 inhibitor sitagliptin signiﬁcantly enhanced the recruitment of CXCR4+CD133+ and CXCR4+Flk-1+ ciPC to the
injured arterial walls. Additional administration of AMD3100 abolished the sitagliptin-mediated recruitment of ciPC (n.s. = not
signiﬁcant; ∗p ≤ 0 05; and ∗∗≤ 0.01). (c, d) The diﬀerent treatments had no eﬀect on the proportion of ciPC in the uninjured arterial walls
(n.s. = not signiﬁcant). (e) Representative dot plots from the FACS analyses.
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contrast to these data, we demonstrated that inhibition of
DPP4 still accelerates endothelial regeneration in Glp1r−/−
mice. Those ﬁndings are in line with our earlier studies in a
C57Bl/6 wild-type mouse model. Besides an improved reen-
dothelialization in sitagliptin-treated mice, we could decrypt
the SDF1-CXCR4 axis as the underlying mechanism of this
eﬀect by using an additional treatment with the CXCR4
receptor blocker AMD3100 in both mouse strains [3]. More-
over, Ohnishi et al. detected an increased recruitment of
endothelium-like cells via the SDF1-CXCR4 axis after
acute ischemic kidney injury to peritubular vessels [36].
Additionally, deﬁciency of the CXCR4 receptor leads to
an impaired endothelial regeneration after vascular injury
[20]. This conﬁrms that enhanced recruitment of circu-
lating progenitor cells is the key mechanism for gliptin-
induced acceleration of endothelial regeneration in this
situation of acute vascular injury and shows that endo-
thelial regeneration is preserved in the setting of murine




































































Figure 4: (a–c) Weigert’s Elastica van Gieson staining of the injured carotid arteries 28 days after vascular injury. (d, e) “Intima-to-media
ratio” and “intima +media to total vessel cross section” were not aﬀected by the diﬀerent treatments (n.s. = not signiﬁcant).









































































































































































































<r 670/14-A>: CD206<r 670/14-A>: CD206
102 103 104 105 0 102 103 104 105 0 102 103 104 105






























Placebo Sitagliptin Sitagliptin and AMD3100
(e)
Figure 5: (a, b) Sitagliptin and sitagliptin +AMD3100 treatment had no signiﬁcant inﬂuence on the total macrophage content in the injured
and also in the uninjured carotid artery (n.s. = not signiﬁcant). (c, d) The diﬀerent treatments had no signiﬁcant inﬂuence on the proportion of
F4/80+Gr-1+ M1 and F4/80+CD206+ M2 macrophages (n.s. = not signiﬁcant). (e) Representative dot plots from FACS analyses. Upper row
shows F4/80+ total macrophages (right quadrant), and bottom row shows F4/80+Gr-1+ M1 (upper left quadrant) and F4/80+CD206+ M2
(bottom right quadrant) macrophages.
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4.2. Circulating Progenitor Cells Are Responsible for the
Improved Endothelial Regeneration. As we previously
demonstrated, ciPC as well as monocyte/macrophages are
involved in vascular regeneration [2, 3]. In a C57Bl/6 mouse
model, we observed an improved endothelial regeneration
from the borders of the lesions after acute arterial injury in
sitagliptin-treated mice. DPP4 inhibition enhanced the
recruitment of ciPC via the SDF1-CXCR4 axis to the injured
sites, where the ciPC presumably induced proliferation of
resident endothelial cells. This assumption is further sup-
ported by the pattern of progressive reendothelialization
from the margins of the injured sites. Hence, a transdiﬀeren-
tiation of the recruited ciPC seems to be unlikely [3].
In this project, we demonstrated an increased recruit-
ment of CXCR4+CD133+ and CXCR4+Flk-1+ ciPC in
sitagliptin-treated Glp1r−/− mice. Due to an improved FACS
protocol, we detected a remarkably higher percentage of
CXCR4+CD133+ and CXCR4+Flk-1+ ciPC. However, the
relative increase of CXCR4+ subtypes after treatment with
sitagliptin is comparable in both our studies.
Notably, GLP1 receptor signaling is abolished in this
mouse model but endothelial regeneration is still accelerated
after sitagliptin treatment. In addition, DPP4 inhibition also
increases local SDF1 levels and enhances the SDF1-CXCR4
axis after ischemia-reperfusion injury in mice after lung
transplantation [37], which conﬁrms the ciPC recruitment
via this pathway after tissue injury. Finally, by using the
CXCR4 receptor blocker AMD3100, we established the
importance of SDF1 mechanistically in the Glp1r−/− mouse
model. We could show that AMD3100 treatment alone
(Glp1r−/− and wild-type) and in combination with sitagliptin
(Glp1r−/−) inhibited endothelial healing as compared to
the placebo-treated mice. These results further support
our theory that inhibition of the CXCR4 receptor on the
progenitor cell surface leads to a reduced recruitment of
these regenerative cells into the injured tissue. Hence,
the increased proportion of recruited ciPC is likely responsi-
ble for the increased regeneration capacity after acute
vascular injury.
Furthermore, we and others have shown that monocytes
express CXCR4 on their surface and that SDF1-CXCR4
signaling is involved in monocyte recruitment and macro-
phage polarization [2, 3, 38]. Sitagliptin treatment primed
monocyte diﬀerentiation towards the regenerative M2 sub-
type instead of the inﬂammatory M1 subtype and led to a
reduced atherosclerosis progression (chronic vascular injury)
in ApoE knockout mice [2]. Chatterjee et al. substantiate our
ﬁndings analyzing cultured human monocytes. They deci-
phered CXCL12- (SDF1) CXCR4 signaling as a pathway
which ﬁrst has the ability to recruit monocytes and second
primes them towards the diﬀerentiation to the M2 subtype
in vitro [38]. However, this mechanism appears to be more
relevant in a chronic setting of high cholesterol-induced
atherogenesis, where M2-type macrophages are involved in
reverse cholesterol transport [39–41]. Instead, in our acute




























Figure 6: (a) 24 h incubation with 10 ng/ml and 100 ng/ml SDF1 leads to an increased scratch closure compared to 1 ng/ml SDF and placebo
treatment (n.s. = not signiﬁcant; ∗∗∗∗p ≤ 0 0001). (b) Representative images of the scratch size immediately after scratch induction (left) and
after 24 h (right).
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disturbances, we did not observe diﬀerences in macrophage
numbers or polarization.
4.3. Gliptin-Mediated Endothelial Regeneration Is
Independent from the GLP1 Receptor. Our data indicate no
diﬀerence in the acceleration of endothelial regeneration by
sitagliptin in mice with intact as compared to deﬁcient
GLP1 receptor signaling. These ﬁndings further highlight
the lack of importance of the GLP-1R in endothelial healing,
consistent with our ﬁndings that the eﬀects mediated by
DPP4 inhibition are SDF1- but not GLP1R-dependent
[3, 29, 42]. Eriksson et al. showed that exendin-4, a
GLP1 receptor agonist, did not have a positive eﬀect on
reendothelialization after balloon injury of the carotid artery
in Sprague-Dawley rats [43] which further supports our
ﬁndings. Using the Glp1r−/−mouse model, we could not only
conﬁrm the ﬁndings from Eriksson et al. but could also show
that the missing GLP1 receptor does not have an additional
negative inﬂuence on endothelial regeneration. As stimula-
tion of the GLP1 receptor as well as the knockout of the
GLP1 receptor does not lead to an alteration of reendotheli-
alization, we can conclude that GLP1 has no relevant
inﬂuence on endothelial cell proliferation after acute vascular
injury in the absence of additional metabolic dysregulation.
Consistent with our previous studies in C57Bl/6 wild-
type mice [3], we could not detect any diﬀerences in neointi-
mal formation in the Glp1r−/− mouse model 28 days after
carotid injury procedure. This data is particularly important,
since former studies by Zernecke et al. postulated that an
enhanced SDF1-CXCR4 axis promotes neointimal hyperpla-
sia by recruitment of bone marrow-derived smooth muscle
cells (BM-SMC) [15]. Karshovska et al. further examined this
controversy and identiﬁed an increased HIF1α expression
after vascular injury as a stimulus for both the upregulated
SDF1 expression in platelets and the resulting recruitment
of BM-SMC [17]. A sole increase of SDF1 concentrations
by inhibition of its degradation thus avoids the problem of
neointimal hyperplasia as SDF1 is located downstream in
the HIF1α-SDF1 signaling cascade. This explains why treat-
ment with sitagliptin has no adverse eﬀects on neointimal
formation after acute endothelial injury.
4.4. SDF1 Has a Direct Proproliferative Eﬀect. In addition to
the gliptin eﬀect on endothelial regeneration via the SDF1-
CXCR4 axis in the Glp1r−/− mouse model, we demonstrated
a direct proregenerative eﬀect of SDF1 on human vascular
endothelial cells (HUVECs) using a scratch assay. This assay
measures a combination of three processes regulating
endothelial healing also in vivo: (inhibition of) apoptosis,
proliferation, and migration. This suggests that, in conjunc-
tion with the enhanced recruitment of ciPC, locally increased
SDF1 levels might further promote endothelial regeneration
after acute vascular injury. Although data on proliferative
SDF1 eﬀects is incomplete, it is known that SDF1 has pos-
itive eﬀects on angiogenesis and endothelial cell migration
[44, 45]. A direct proproliferative SDF1 eﬀect was con-
ﬁrmed, for example, for astrocytes [46], but not yet for
human endothelial cells in microvasculature. Neuhaus et al.
previously described an increased proliferation of human
aortic endothelial cells via SDF1 induced enhanced VEGF
expression [44]. This synergism of SDF1 and VEGF might
be a possible underlying mechanism for the increased
HUVEC proliferation and improved scratch closure pro-
moted by high SDF1 concentrations in our experiment. Fur-
ther studies are needed in the future for a detailed elucidation
of the direct and indirect SDF1-mediated proproliferative
eﬀects on the diseased endothelium.
5. Conclusion
Pharmacological inhibition of the enzyme DPP4 reduces
SDF1 cleavage and therefore increases the local SDF1
concentration after vascular injury and supports the SDF1-
CXCR4-dependent recruitment of circulating progenitor
cells. Using various methods, we conﬁrmed the SDF1-
CXCR4 axis as a crucial signaling pathway for endothelial
regeneration after acute vascular injury, not only in wild-
type animals but also in the absence of functional GLP1
receptor signaling.
Our study provides novel insight into the direct and
indirect eﬀects of SDF1-CXCR4 signaling on endothelial
regeneration. Sitagliptin acted through both, the recruitment
of supportive cell types and directly on endothelial cell regen-
erative capacity. These ﬁndings further support the assump-
tion that endothelial healing occurs from the borders of the
injured area by proliferation of resident endothelial cells [3].
In addition, we newly show that the proregenerative
eﬀects of sitagliptin are preserved in the absence of the
GLP1 receptor. In this situation of acute vascular injury in
the absence of dysglycemia, GLP1 has no relevant inﬂuence
on endothelial cell proliferation and gliptins act on the
vasculature independently from the incretin GLP1. We
could identify the SDF1-CXCR4 axis as the main factor
of gliptin-mediated endothelial regeneration after acute
vascular injury.
Our data therefore underline the therapeutic potential of
gliptin treatment after acute vascular injury that occurs in
vascular diseases or vascular interventional therapies. Quick
reendothelialization is essential for the prevention of vascular
thromboses, neointima formation, in-stent restenoses, and
vascular remodeling. Thus, as a well-tolerated class of drugs
with proven cardiovascular safety, gliptins may represent
potential candidates for therapy after acute vascular injury.
Notably, sitagliptin has also been shown to robustly prevent
SDF-1 degradation in human subjects with T2DM [47].
Large animal experiments and randomized human clinical
trials should therefore examine the therapeutic potential of
DPP4 inhibitors in vascular diseases, to ensure drug eﬃ-
ciency and to prepare the way for a use of DPP4 inhibitors
for vascular regeneration.
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